Effect of intravitreal anti-vascular endothelial growth factor therapy on the risk of arterial thromboembolic events: A meta-analysis

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Cheng, Jin Wei ^a   Cheng, Shi Wei ^b   Lu, Guo Cai ^c   Wei, Rui Li ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b LUDONG UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; MONOCLONAL ANTIBODY; PEGAPTANIB; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN ANTIBODY; VERTEPORFIN;

ARTERIAL THROMBOEMBOLISM; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; EYE DISEASE; HEART INFARCTION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SIDE EFFECT; STUDY DESIGN; SYSTEMATIC REVIEW;

HUMANS; INTRAVITREAL INJECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOEMBOLISM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84864071635     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041325     Document Type: Article

References (41)

1. Folkman J, (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
2. Hicklin DJ, Ellis LM, (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-27.
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-42.
4. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-50.
5. Moshfeghi AA, Puliafito CA, (2005) Pegaptanib sodium for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 14: 671-82.
6. Pieramici DJ, Avery RL, (2006) Ranibizumab: treatment in patients with neovascular age-related macular degeneration. Expert Opin Biol Ther 6: 1237-45.
7. Andreoli CM, Miller JW, (2007) Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 18: 502-8.
8. Ciulla TA, Rosenfeld PJ, (2009) Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr Opin Ophthalmol 20: 166-74.
9. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, et al. (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99: 1232-9.
10. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S, (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300: 2277-85.
11. Hyman L, Schachat AP, He Q, Leske MC, (2000) Hypertension, cardiovascular disease, and age-related macular degeneration. Arch Ophthalmol 118: 351-8.
12. Hogg RE, Woodside JV, Gilchrist SE, Graydon R, Fletcher AE, et al. (2008) Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization. Ophthalmology 115: 1046-1052.e2.
13. Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T, (2009) Cerebrovascular accidents in ranibizumab. Ophthalmology 116: 362.
14. Antiplatelet Trialists' Collaboration, (1994) Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308: 81-106.
15. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
17. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-58.
18. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-48.
19. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-88.
20. Lau J, Ioannidis JP, Schmid CH, (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820-6.
21. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-34.
22. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, Adamis AP, et al (2006) Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113: 992-1001.e6.
23. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, et al. (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-31.
24. Antoszyk AN, Tuomi L, Chung CY, Singh A; FOCUS Study Group (2008) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 145: 862-74.
25. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, et al. (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116: 57-65.e5.
26. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, et al. (2010) A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 117: 1078-1086.e2.
27. Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, et al. (2010) Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 340: c2459.
28. Abraham P, Yue H, Wilson L, (2010) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol. 150: 315-324.e1.
29. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, et al. (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33: 2399-405.
30. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, et al. (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118: 1594-602.
31. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, et al. (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118: 2041-9.
32. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, et al (2011) Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118: 609-14.
33. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, et al. (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118: 615-25.
34. Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS; Macugen 1013 Study Group (2011) A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 118: 1107-18.
35. Trempe C, (2011) Ranibizumab for age-related macular degeneration. N Engl J Med 364: 581-2.
36. Nissen SE, Wolski K, (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-71.
37. Wong TY, Larsen EK, Klein R, Mitchell P, Couper DJ, et al. (2005) Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. Ophthalmology 112: 540-7.
38. Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, et al. (2011) Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol 95: 308-17.
39. Curtis LH, Hammill BG, Schulman KA, Cousins SW, (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol128: 1273-9.
40. French DD, Margo CE, (2011) Age-related macular degeneration, anti-vascular endothelial growth factor agents, and short-term mortality: a postmarketing medication safety and surveillance study. Retina 31: 1036-42.
41. Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, et al. (2007) Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res 101: 948-56.